STOCK TITAN

Reata Pharmaceuticals, Inc. - RETA STOCK NEWS

Welcome to our dedicated page for Reata Pharmaceuticals news (Ticker: RETA), a resource for investors and traders seeking the latest updates and insights on Reata Pharmaceuticals stock.

Reata Pharmaceuticals, Inc. (NASDAQ: RETA) is a clinical-stage biopharmaceutical company dedicated to developing groundbreaking therapeutics for patients with serious or life-threatening diseases. By focusing on the intricate molecular pathways that regulate cellular metabolism and inflammation, Reata aims to innovate treatments that address significant medical needs.

Reata's core expertise lies in targeting the transcription factor NRF2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company's two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, are designed to leverage this mechanism to treat a range of conditions.

Bardoxolone methyl is currently being investigated for its potential benefits in treating chronic kidney disease, while omaveloxolone is under development for the treatment of Friedreich's ataxia, a debilitating neuromuscular disorder. These candidates have shown promising results in clinical trials, positioning Reata as a key player in the biopharmaceutical industry.

Reata has forged strong partnerships with leading healthcare organizations to advance its research and development efforts. Financially, the company remains robust, securing funding through strategic collaborations and public offerings. This financial stability allows Reata to continue its pioneering work in the biopharmaceutical sector.

In recent developments, Reata has achieved significant milestones in its clinical trials, receiving positive feedback from regulatory authorities and expanding its research portfolio. These achievements underscore the company's commitment to delivering innovative therapies that can transform patient outcomes.

For investors and stakeholders, Reata represents a dynamic and promising investment opportunity in the biopharmaceutical industry. With a clear focus on addressing unmet medical needs and a strong pipeline of potential therapies, Reata is well-positioned for future growth and success.

Rhea-AI Summary

Reata Pharmaceuticals (Nasdaq: RETA) announced its participation in two upcoming investor conferences. Management will present at the Bank of America Merrill Lynch Global Healthcare Conference on May 12, 2021, and at the Jefferies Virtual Healthcare Conference on June 2, 2021. Reata, a clinical-stage biopharmaceutical company, focuses on developing therapeutics targeting molecular pathways related to metabolism and inflammation. Key candidates include bardoxolone methyl and omaveloxolone, which are investigational drugs with safety and efficacy not yet established.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
conferences
-
Rhea-AI Summary

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) announced it will report its financial results and update on development programs pre-market on May 6, 2021. A conference call will be held the same day at 8:30 am ET, accessible by phone or via webcast. Financial results will be shared in an earnings press release available on Reata's website prior to the call. The audio of the call will be accessible for 90 days post-event. Reata focuses on developing therapeutics targeting metabolic and inflammatory pathways, with key candidates being bardoxolone methyl and omaveloxolone, which are still investigational.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.69%
Tags
conferences
-
Rhea-AI Summary

Reata Pharmaceuticals announced the acceptance of its New Drug Application for bardoxolone methyl by the FDA to treat chronic kidney disease caused by Alport syndrome. Approximately 30,000-60,000 patients in the U.S. are affected, and if approved, bardoxolone will be the first therapy available for this condition. The PDUFA date is set for February 25, 2022. Data from the CARDINAL Phase 3 trial indicated significant improvements in kidney function, and bardoxolone showed a favorable safety profile.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.02%
Tags
none
Rhea-AI Summary

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) announced the appointment of Christy J. Oliger and Shamim Ruff to its Board of Directors, effective April 15, 2021. CEO Warren Huff expressed optimism about their experience as the company prepares for the commercial launch of bardoxolone methyl for treating chronic kidney disease due to Alport syndrome. Oliger has nearly 30 years in biopharmaceuticals, while Ruff has extensive regulatory experience. Both are expected to contribute significantly to advancing Reata's innovative therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.73%
Tags
management
-
Rhea-AI Summary

Reata Pharmaceuticals (Nasdaq: RETA) announced the presentation of clinical data for bardoxolone methyl at two nephrology conferences. The World Congress of Nephrology 2021 will feature an interim analysis of the EAGLE trial focusing on chronic kidney disease due to Alport syndrome. The ERA-EDTA Congress will present pediatric data from the Phase 3 CARDINAL trial. Bardoxolone, an investigational drug, is recognized for its therapeutic potential in CKD and has received Orphan Drug designation from the FDA and European Commission for Alport syndrome treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.05%
Tags
conferences
-
Rhea-AI Summary

Reata Pharmaceuticals (Nasdaq: RETA) announced its first NDA submission for bardoxolone in Alport syndrome, backed by Phase 3 trial data. This breakthrough potentially positions bardoxolone as the first approved treatment for CKD due to Alport syndrome. The company reported a solid cash balance of $818.2 million at year-end 2020, ensuring a funding runway through mid-2024. Key trial updates include over 220 patients enrolled in the FALCON trial for ADPKD and the initiation of the MERLIN trial for CKD. Financial results show a GAAP net loss decrease to $247.8 million for 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
Rhea-AI Summary

Reata Pharmaceuticals (Nasdaq: RETA) announced the submission of a New Drug Application (NDA) for bardoxolone methyl to the FDA for treating chronic kidney disease caused by Alport syndrome. The NDA is based on data from the Phase 3 CARDINAL trial, which showed a significant improvement in kidney function over placebo. A request for Priority Review has been made, potentially accelerating the review process to eight months. If approved, bardoxolone would be the first therapy specifically for CKD due to Alport syndrome, addressing a critical need among patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
none
-
Rhea-AI Summary

Reata Pharmaceuticals (Nasdaq: RETA) will report its fourth quarter and full year 2020 financial results on March 1, 2021, before market open. A conference call is scheduled for the same day at 8:30 am ET, accessible by phone or via webcast. The earnings press release will be available on Reata's website shortly before the call and will remain accessible for one year. Reata develops innovative therapies targeting serious diseases by focusing on cellular metabolism and inflammation. Its lead candidates are bardoxolone methyl and omaveloxolone, which are investigational drugs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.78%
Tags
conferences
-
Rhea-AI Summary

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) announced the successful closing of its public offering of 2,000,000 shares of Class A common stock at $140.85 per share, generating gross proceeds of $281.7 million. The underwriters also received a 30-day option to buy an additional 300,000 shares. Barclays Capital and Goldman Sachs served as joint book-running managers for the offering. The securities were offered under an effective shelf registration statement, with details filed with the SEC. Reata develops innovative therapeutics targeting serious diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
none
Rhea-AI Summary

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) has priced a public offering of 2,000,000 shares of its Class A common stock at $140.85 per share, yielding gross proceeds of $281.7 million. The offering includes a 30-day option for underwriters to purchase an additional 300,000 shares. The offering is subject to customary closing conditions and is expected to conclude on December 4, 2020. Barclays Capital Inc. and Goldman Sachs & Co. LLC are acting as joint book-running managers for this offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.1%
Tags
none

FAQ

What is the market cap of Reata Pharmaceuticals (RETA)?

The market cap of Reata Pharmaceuticals (RETA) is approximately 6.6B.

What is Reata Pharmaceuticals, Inc.?

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops novel therapeutics for serious or life-threatening diseases.

What are Reata's most advanced clinical candidates?

Reata's most advanced clinical candidates are bardoxolone methyl and omaveloxolone.

What does NRF2 target?

NRF2 targets the restoration of mitochondrial function, reduction of oxidative stress, and resolution of inflammation.

What diseases are bardoxolone methyl and omaveloxolone being developed to treat?

Bardoxolone methyl is being developed for chronic kidney disease, while omaveloxolone is being developed for Friedreich's ataxia.

What recent achievements has Reata Pharmaceuticals made?

Reata has achieved significant milestones in clinical trials and received positive feedback from regulatory authorities.

Who are Reata's partners?

Reata has partnerships with leading healthcare organizations to advance its research and development efforts.

How is Reata Pharmaceuticals financially sustained?

Reata secures funding through strategic collaborations and public offerings.

Why is Reata considered a promising investment?

Reata is considered a promising investment due to its focus on unmet medical needs and a strong pipeline of potential therapies.

What is the focus of Reata's research?

Reata's research focuses on targeting molecular pathways involved in regulating cellular metabolism and inflammation.

What is the significance of Reata's work in the biopharmaceutical industry?

Reata's work is significant as it aims to deliver innovative therapies that can transform patient outcomes for serious or life-threatening diseases.

Reata Pharmaceuticals, Inc.

Nasdaq:RETA

RETA Rankings

RETA Stock Data

6.57B
27.34M
4.1%
88.47%
6.28%
Biotechnology
Healthcare
Link
United States
Plano